Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 4/20 | 0.41 |
| ▸ | S1PR3 | Q99500 | 4/20 | 0.41 |
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | NAAA | Q02083 | 1/20 | 0.35 |
| ▸ | RET | P07949 | 1/20 | 0.35 |
| ▸ | GABRA1 | P14867 | 4/20 | 0.35 |
| ▸ | GABRB2 | P47870 | 4/20 | 0.35 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.35 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.34 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.34 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10302004 | 0.91 | FFAR4 (0.38) | S1PR1S1PR3FFAR4NAAAGABRA1 | |
| SCHEMBL10301999 | 0.90 | GABRA1 (0.42) | S1PR1S1PR3FFAR4NAAAGABRA1 | |
| SCHEMBL10302001 | 0.89 | FFAR4 (0.37) | FFAR4GABRA1GABRB2CYP4F2CYP4A11 | |
| SCHEMBL10302027 | 0.89 | GABRA1 (0.43) | S1PR1S1PR3FFAR4NAAAGABRA1 | |
| SCHEMBL12740102 | 0.89 | S1PR1 (0.40) | S1PR1S1PR3FFAR4RETGABRA1 | |
| SCHEMBL12735566 | 0.89 | S1PR1 (0.40) | S1PR1S1PR3FFAR4RETGABRA1 | |
| SCHEMBL10302529 | 0.88 | FFAR1 (0.40) | S1PR1S1PR3FFAR4NAAAFFAR1 | |
| SCHEMBL10302006 | 0.88 | FFAR4 (0.39) | S1PR1S1PR3FFAR4NAAAGABRA1 | |
| SCHEMBL10302026 | 0.88 | FFAR4 (0.41) | S1PR1S1PR3FFAR4NAAARET | |
| SCHEMBL10301998 | 0.87 | RARB (0.44) | S1PR1FFAR4HTTGABRA1GABRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8216489-B2 | Three-ring liquid crystal compound having lateral fluorine, liquid crystal composition, and liquid crystal display device | JNC CORPORATION (JP) | 2012-07-10 | — | — | US | disclosed |
| US-20110037024-A1 | THREE-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE | CHISSO CORPORATION (JP) | 2011-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110037024-A1 | THREE-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE | LEF1, LAS1L, L3MBTL3 | S1PR1 1915/4885S1PR3 1056/4885FFAR4 1669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.